First Wild Card winner, DX-Labtrack, receiving €2 million to develop real-time sample monitoring
Technical University of Munich, Germany, provides incubator support
Following months of training and competition, DX-Labtrack was chosen to receive €2 million in support to create a start-up. They will be hosted at the facilities of of Technical University of Munich, Germany, which competed to serve as DX-Labtrack’s incubator.
One more Wild Card winner is expected to be announced soon, and to receive similar support.
The announcenment of DX-Labtrack as the first winner of support through EIT Health’s new Wild Card programme was the culmination of a year of preparation, which included setting challenges for teams to pursue, picking teams, training, mentoring, and a competition involving medical professionals, entrepreneurs, technologists and data experts. Out of 70 qualified applicants, 30 of the best were invited to create teams tasked with proposing workable, transformative concepts to address pressing healthcare challenges identified by the EIT Health community.
“Being part of Wild Card is an exceptional challenge and a gigantic step forward for us personally and for the project. Through the solution for surveillance of blood samples, DX-Labtrack will make it possible to change medical diagnostics from a trust-based to an evidence-based system. Medical doctors and patients will be sure that the analytical results are actually correct,” Dr. Hans Maria Heyn, a co-founder of DX-Labtrack, said
Jan-Philipp Beck, EIT Health CEO, added: “We are proud to wrap up a successful first year of the Wild Card programme. We are looking forward to seeing the winning teams thriving and turning their innovative ideas into reality. We are pleased to support these exciting projects.”
About DX-Labtrack GmbH
DX-Labtrack provides a real-time monitoring solution to ensure the quality of blood samples, from the time they are taken from the patient to the point where they reach the lab. The solution’s cutting-edge technology enables digital monitoring and quality assurance. It connects and aggregates all relevant data on the quality of human samples and produces an individual human sample fingerprint. The result is the kind of biologically reliable lab tests that make personalised medicine possible.
Incubator: DX-Labtrack established cooperation with Technical University of Munich, an EIT Health Core Partner in Munich, Germany.
Team: Dr. Julia Flottoto, Dr. Yannick Timo Boge, Dr. Malte Dancker, Dr. Hans Maria Heyn